CBI Stock Chart & Stats
25.90
-0.50(-1.93%)
At close: 4:00 PM EDT
25.90
-0.50(-1.93%)
Day’s Range― - ―
52-Week Range23.70 - 44.00
Previous CloseN/A
Volume0.00
Average Volume (3M)153.57K
Market Cap
₪37.64M
Enterprise Value61.33M
Total Cash (Recent Filing)₪1.69M
Total Debt (Recent Filing)₪17.75M
Price to Earnings (P/E)―
Beta0.44
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding156,846,200
10 Day Avg. Volume149,239
30 Day Avg. Volume153,567
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)57.10
P/FCF Ratio-11.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Clal Biotech News
CBI FAQ
What was Clal Biotechnology Industries Ltd’s price range in the past 12 months?
Clal Biotechnology Industries Ltd lowest stock price was 23.70 and its highest was 44.00 in the past 12 months.
What is Clal Biotechnology Industries Ltd’s market cap?
Clal Biotechnology Industries Ltd’s market cap is ₪37.64M.
When is Clal Biotechnology Industries Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Clal Biotechnology Industries Ltd’s earnings last quarter?
Clal Biotechnology Industries Ltd released its earnings results on Aug 19, 2021. The company reported -22 earnings per share for the quarter, missing the consensus estimate of N/A by -22.
Is Clal Biotechnology Industries Ltd overvalued?
According to Wall Street analysts Clal Biotechnology Industries Ltd’s price is currently Overvalued.
Does Clal Biotechnology Industries Ltd pay dividends?
Clal Biotechnology Industries Ltd pays a Notavailable dividend of 22.372 which represents an annual dividend yield of N/A. See more information on Clal Biotechnology Industries Ltd dividends here
What is Clal Biotechnology Industries Ltd’s EPS estimate?
Clal Biotechnology Industries Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clal Biotechnology Industries Ltd have?
Clal Biotechnology Industries Ltd has 156,846,200 shares outstanding.
What happened to Clal Biotechnology Industries Ltd’s price movement after its last earnings report?
Clal Biotechnology Industries Ltd reported an EPS of -22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Clal Biotechnology Industries Ltd?
Currently, no hedge funds are holding shares in IL:CBI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clal Biotechnology Industries Ltd
Clal Biotechnology Industries Ltd. (CBI) operates as a venture capital and private equity firm, primarily funding innovative companies within the life sciences, medical device, biopharmaceutical, and broader biotechnology sectors. The firm is adept at investing across a comprehensive spectrum of development stages, ranging from initial incubation, seed, and startup phases, through early, emerging, mid, and late-stage ventures, including pre-clinical development, PIPEs, and growth capital financing. CBI strategically targets companies based in the United States and Israel, typically deploying between $0.5 million and $10 million into each investment. It frequently assumes the role of a lead investor and a significant shareholder, often securing a board seat within its portfolio companies. Established in July 1998, CBI utilizes the personal capital of its management team for its investments. Its primary base is in Tel Aviv, Israel, complemented by an additional office in Cambridge, Massachusetts. The firm formerly functioned as a subsidiary of Clal Industries and Investments Ltd.